Entinostat + Pembrolizumab in Advanced Solid Tumors (Continuation)

Phase 1, randomised, open-label trial of entinostat in solid tumor (3 arms), sponsored by Syndax Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) resulting in permanent discontinuation, Changes from baseline in laboratory results and 2 more. Started Sep 2016; status: completed.